₹672.05▲4.44%
Source: S&P Global Market Intelligence
Day's Low
Day's High
52 Week's Low
52 Week's High
Returns % | |
1 Month Return | + 7.93 % |
3 Month Return | + 21.15 % |
1 Year Return | + 104.21 % |
Market Stats | |
Previous Close | ₹643.45 |
Open | ₹647.00 |
Volume | 3.03L |
Upper Circuit | - |
Lower Circuit | - |
Market Cap | ₹6,292.36Cr |
P/E Ratio | 174.85 |
PEG Ratio | 23.56 |
Market Cap | ₹6,292.36 Cr |
P/B Ratio | 0.94 |
EPS | 13.43 |
Organisation | Shilpa Medicare Ltd |
Headquarters | |
Industry | Pharmaceuticals |
E-voting on shares | Click here to vote |
Key events for Shilpa Medicare Ltd
Shilpa Biologicals, a subsidiary of Shilpa Medicare, has received approval for its high concentration Adalimumab biosimilar from the Moroccan Ministry of Health. This is the first international market approval for the drug, and the company plans to submit dossiers in more than 15 emerging markets.
Shilpa Medicare Reports Revenue Growth and Profit in FY24 - 17 Jul, 2024
Shilpa Medicare Limited's Revenue from Operations grew by 10.08% to Rs. 1,152 Crores in FY24, accompanied by a profit of Rs. 32 Crores. FII/FPI increased their holding in Q1FY25.
Shilpa Medicare Passes GMP Inspections - 10 Jul, 2024
Shilpa Medicare's subsidiary, Shilpa Pharma Lifesciences, and its Raichur API facility pass GMP inspections by Brazilian and Global Regulatory Authorities respectively. The company reports a consolidated net profit of Rs 24.50 crore in Q4 FY24.
Shilpa Medicare Shares Surge on Positive Clinical Trial Results - 05 Jul, 2024
Shilpa Medicare's stock surged up to 16.25% following positive clinical trial results for its kidney disease drug. The company partnered with Unicycive to provide end-to-end CDMO services and is set to receive $10M milestone income. Additionally, one of its subsidiaries acquired a stake in Mylab Discovery Solutions Limited. Despite slower-than-industry revenue growth, investors are hoping for a turnaround in the company's business prospects.
Shilpa Medicare Insiders Show Vested Interest in Company's Growth - 26 Jun, 2024
Insiders own 51% of Shilpa Medicare, with CEO Vishnukanth Bhutada increasing holdings by 10%. Institutional investors also have a fair amount of stake. Private companies own 8.7%.
Shilpa Medicare Facility Passes US FDA Inspection - 25 Jun, 2024
Shilpa Medicare's Bio-Analytical Laboratory in Hyderabad, India passed a US FDA inspection with no observations and was classified as No Action Indicated (NAI). The company reported a net profit of Rs 24.50 crore in Q4 FY24.
Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.
Profit Spike
Netprofit is up for the last 5 quarters, -8.04 Cr → 24.5 Cr (in ₹), with an average increase of 238.6% per quarter
Best in 1 Year
In the last 1 year, SHILPAMED has outperformed top 5 stocks with highest market-cap in Pharmaceuticals
Retail Holding Up
Retail Investor have increased holdings from 38.39% to 38.92% in Jun 2024 quarter
Price Rise
In the last 6 months, SHILPAMED stock has moved up by 100.5%
MF Holding Up
Mutual Funds have increased holdings from 5.01% to 5.03% in Jun 2024 quarter
Revenue Rich
Revenue is up for the last 2 quarters, 288.7 Cr → 300.32 Cr (in ₹), with an average increase of 3.9% per quarter
Promoter Holding Unchanged
Promoters holdings remained unchanged at 44.39% of holdings in Jun 2024 quarter
Against Peers
In the last 3 years, Sun Pharmaceuticals Industries Ltd has given 127.7% return, outperforming this stock by 128.7%
FII Holding Down
Foreign Institutions have decreased holdings from 9.68% to 9.08% in Jun 2024 quarter
Q'1 24 | Q/Q Change | |
---|---|---|
Revenue | ₹291.69Cr | ↑1.72% |
Net Income | ₹24.50Cr | ↑421.28% |
Net Profit Margin | 8.40% | ↑412.20% |
2023 | Y/Y Change | |
---|---|---|
Revenue | ₹1,050.11Cr | ↓8.33% |
Net Income | -₹30.92Cr | ↓151.04% |
Net Profit Margin | -2.94% | ↓155.58% |
2023 | Y/Y Change | |
---|---|---|
Total Assets | ₹2,595.86Cr | ↓12.48% |
Total Liabilities | ₹478.28Cr | ↓46.88% |
2023 | Y/Y Change | |
---|---|---|
Operating Cash Flow | ₹2.08Cr | ↓98.80% |
Investors | Holdings % | FY Quarter | 3M change |
---|---|---|---|
Promoter Holdings | 44.39% | 0.00 | |
Foreign Institutions | 9.08% | ||
Mutual Funds | 5.03% | 0.39 | |
Retail Investors | 38.92% | 1.38 | |
Others | 2.58% | 2.06 |
Shilpa Medicare Ltd in the last 5 years
Lowest (-6579.29x)
March 28, 2024
Industry (56.07x)
July 23, 2024
Today (174.85x)
July 23, 2024
Highest (503.73x)
February 21, 2023
Shilpa Medicare Ltd’s net profit jumped 404.73% since last year same period to ₹24.50Cr in the Q4 2023-2024. On a quarterly growth basis, Shilpa Medicare Ltd has generated 434.93% jump in its net profits since last 3-months.
Read More about Earnings ResultsIn the quarter ending March 2022, Shilpa Medicare Ltd has declared dividend of ₹1.10 - translating a dividend yield of 0.34%.
Read More about DividendsBearish
Neutral
Bullish
Shilpa Medicare Ltd is currently in a Bullish trading position according to technical analysis indicators.
Shilpa Medicare Ltd (SHILPAMED) share price today is ₹672.05
Shilpa Medicare Ltd is listed on NSE
Shilpa Medicare Ltd is listed on BSE
PE Ratio of Shilpa Medicare Ltd is 174.85
PE ratio = Shilpa Medicare Ltd Market price per share / Shilpa Medicare Ltd Earnings per share
Today’s traded volume of Shilpa Medicare Ltd(SHILPAMED) is 3.03L.
Today’s market capitalisation of Shilpa Medicare Ltd(SHILPAMED) is ₹6292.36Cr.
Shilpa Medicare Ltd(SHILPAMED | Price |
---|---|
52 Week High | ₹685 |
52 Week Low | ₹296.8 |
Shilpa Medicare Ltd(SHILPAMED) share price is ₹672.05. It is down -1.89% from its 52 Week High price of ₹685
Shilpa Medicare Ltd(SHILPAMED) share price is ₹672.05. It is up 126.43% from its 52 Week Low price of ₹296.8
Shilpa Medicare Ltd(SHILPAMED | Returns |
---|---|
1 Day Returns | 28.6% |
1 Month Returns | 7.93% |
3 Month Returns | 21.15% |
1 Year Returns | 104.21% |